<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31833172</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4833</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>182</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of medical genetics. Part A</Title>
          <ISOAbbreviation>Am J Med Genet A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TFE3-associated neurodevelopmental disorder: A distinct recognizable syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>584</StartPage>
          <EndPage>590</EndPage>
          <MedlinePgn>584-590</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajmg.a.61437</ELocationID>
        <Abstract>
          <AbstractText>The transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3) gene encodes a transcription factor that regulates embryonic stem cell (ESC) differentiation. Its phosphorylation by the lysosomal Rag GTPase signaling pathway leads to cytoplasmic sequestration and inactivation promoting ESC differentiation and exit from pluripotency. Somatic translocations of this X-linked gene cause papillary renal cell carcinoma in which nuclear accumulation of the TFE3 oncoprotein is one of the most significant histopathologic characteristics. Early this year, Villegas et al. identified missense mutations in a TFE3 domain required for cytoplasmic inactivation as potentially causal for a mosaic human developmental disorder. They published five patients with de novo TFE3 nonsynonymous missense variants, four females and one male, with severe intellectual disability (5/5), coarse facial features (4/5), and Blaschkoid pigmentary mosaicism (4/5). The only male described has somatic mosaicism. All patients had normal brain Magnetic Resonance Imagings (MRIs). We present two unrelated females with this distinctive phenotype including the above triad along with other features not previously well described. Both were found to have de novo heterozygous variants in TFE3 on whole exome sequencing, one nonsynonymous missense, and one canonical splice site variant, thereby expanding the phenotypic and mutational spectrum for this disorder. Interestingly, due to significant coarsening of the facial features, both patients were initially thought to have a lysosomal storage disorder but enzyme screening and brain MRIs were negative.</AbstractText>
          <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Diaz</LastName>
            <ForeName>Jullianne</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berger</LastName>
            <ForeName>Seth</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leon</LastName>
            <ForeName>Eyby</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-1852-2849</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Med Genet A</MedlineTA>
        <NlmUniqueID>101235741</NlmUniqueID>
        <ISSNLinking>1552-4825</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051778">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C069203">TFE3 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051778" MajorTopicYN="N">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016464" MajorTopicYN="N">Lysosomal Storage Diseases</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065886" MajorTopicYN="N">Neurodevelopmental Disorders</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073359" MajorTopicYN="N">Whole Exome Sequencing</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">
TFE3</Keyword>
        <Keyword MajorTopicYN="Y">X-linked</Keyword>
        <Keyword MajorTopicYN="Y">lysosomal disorder</Keyword>
        <Keyword MajorTopicYN="Y">pigmentary mosaicism</Keyword>
        <Keyword MajorTopicYN="Y">transcription factor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31833172</ArticleId>
        <ArticleId IdType="doi">10.1002/ajmg.a.61437</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Clark, J., Lu, Y. J., Sidhar, S. K., Parker, C., Gill, S., Smedley, D., … Cooper, C. S. (1997). Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 15(18), 2233-2239. https://doi.org/10.1038/sj.onc.1201394</Citation>
        </Reference>
        <Reference>
          <Citation>Colaço, A., &amp; Jäättelä, M. (2017). Ragulator-a multifaceted regulator of lysosomal signaling and trafficking. The Journal of Cell Biology, 216(12), 3895-3898. https://doi.org/10.1083/jcb.201710039</Citation>
        </Reference>
        <Reference>
          <Citation>Lim, C. Y., &amp; Zoncu, R. (2016). The lysosome as a command-and-control center for cellular metabolism. The Journal of Cell Biology, 214(6), 653-664. https://doi.org/10.1083/jcb.201607005</Citation>
        </Reference>
        <Reference>
          <Citation>McRae, J. F., Clayton, S., Fitzgerald, T. W., Kaplanis, J., Prigmore, E., Rajan, D., … Hurles, M. E. (2017). Prevalence and architecture of de novo mutations in developmental disorders. Nature, 542(7642), 433-438. https://doi.org/10.1038/nature21062</Citation>
        </Reference>
        <Reference>
          <Citation>Pastore, N., Vainshtein, A., Klisch, T., Armani, A., Huynh, T., Herz, N. J., … Ballabio, A. (2017). TFE3 regulates whole-body energy metabolism in cooperation with TFEB. EMBO Molecular Medicine, 9(5), 605-621. https://doi.org/10.15252/emmm.201607204</Citation>
        </Reference>
        <Reference>
          <Citation>Slade, L., &amp; Pulinilkunnil, T. (2017). The MiTF/TFE family of transcription factors: Master regulators of organelle signaling, metabolism, and stress adaptation. Molecular Cancer Research, 15(12), 1637-1643. https://doi.org/10.1158/1541-7786.MCR-17-0320</Citation>
        </Reference>
        <Reference>
          <Citation>Villegas, F., Lehalle, D., Mayer, D., Rittirsch, M., Stadler, M. B., Zinner, M., … Betschinger, J. (2019). Lysosomal signaling licenses embryonic stem cell differentiation via inactivation of Tfe3. Cell Stem Cell, 24(2), 257-270. https://doi.org/10.1016/j.stem.2018.11.021</Citation>
        </Reference>
        <Reference>
          <Citation>Yin, X., Wang, B., Gan, W., Zhuang, W., Xiang, Z., Han, X., &amp; Li, D. (2019). TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas. Journal of Experimental &amp; Clinical Cancer Research, 38(1), 119. https://doi.org/10.1186/s13046-019-1101-7</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31833172</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4833</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>182</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of medical genetics. Part A</Title>
          <ISOAbbreviation>Am J Med Genet A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TFE3-associated neurodevelopmental disorder: A distinct recognizable syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>584</StartPage>
          <EndPage>590</EndPage>
          <MedlinePgn>584-590</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajmg.a.61437</ELocationID>
        <Abstract>
          <AbstractText>The transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3) gene encodes a transcription factor that regulates embryonic stem cell (ESC) differentiation. Its phosphorylation by the lysosomal Rag GTPase signaling pathway leads to cytoplasmic sequestration and inactivation promoting ESC differentiation and exit from pluripotency. Somatic translocations of this X-linked gene cause papillary renal cell carcinoma in which nuclear accumulation of the TFE3 oncoprotein is one of the most significant histopathologic characteristics. Early this year, Villegas et al. identified missense mutations in a TFE3 domain required for cytoplasmic inactivation as potentially causal for a mosaic human developmental disorder. They published five patients with de novo TFE3 nonsynonymous missense variants, four females and one male, with severe intellectual disability (5/5), coarse facial features (4/5), and Blaschkoid pigmentary mosaicism (4/5). The only male described has somatic mosaicism. All patients had normal brain Magnetic Resonance Imagings (MRIs). We present two unrelated females with this distinctive phenotype including the above triad along with other features not previously well described. Both were found to have de novo heterozygous variants in TFE3 on whole exome sequencing, one nonsynonymous missense, and one canonical splice site variant, thereby expanding the phenotypic and mutational spectrum for this disorder. Interestingly, due to significant coarsening of the facial features, both patients were initially thought to have a lysosomal storage disorder but enzyme screening and brain MRIs were negative.</AbstractText>
          <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Diaz</LastName>
            <ForeName>Jullianne</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berger</LastName>
            <ForeName>Seth</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leon</LastName>
            <ForeName>Eyby</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-1852-2849</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Genetics, Rare Disease Institute, Children's National Health System, Washington, District of Columbia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Med Genet A</MedlineTA>
        <NlmUniqueID>101235741</NlmUniqueID>
        <ISSNLinking>1552-4825</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051778">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C069203">TFE3 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051778" MajorTopicYN="N">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016464" MajorTopicYN="N">Lysosomal Storage Diseases</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065886" MajorTopicYN="N">Neurodevelopmental Disorders</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073359" MajorTopicYN="N">Whole Exome Sequencing</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">
TFE3</Keyword>
        <Keyword MajorTopicYN="Y">X-linked</Keyword>
        <Keyword MajorTopicYN="Y">lysosomal disorder</Keyword>
        <Keyword MajorTopicYN="Y">pigmentary mosaicism</Keyword>
        <Keyword MajorTopicYN="Y">transcription factor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31833172</ArticleId>
        <ArticleId IdType="doi">10.1002/ajmg.a.61437</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Clark, J., Lu, Y. J., Sidhar, S. K., Parker, C., Gill, S., Smedley, D., … Cooper, C. S. (1997). Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 15(18), 2233-2239. https://doi.org/10.1038/sj.onc.1201394</Citation>
        </Reference>
        <Reference>
          <Citation>Colaço, A., &amp; Jäättelä, M. (2017). Ragulator-a multifaceted regulator of lysosomal signaling and trafficking. The Journal of Cell Biology, 216(12), 3895-3898. https://doi.org/10.1083/jcb.201710039</Citation>
        </Reference>
        <Reference>
          <Citation>Lim, C. Y., &amp; Zoncu, R. (2016). The lysosome as a command-and-control center for cellular metabolism. The Journal of Cell Biology, 214(6), 653-664. https://doi.org/10.1083/jcb.201607005</Citation>
        </Reference>
        <Reference>
          <Citation>McRae, J. F., Clayton, S., Fitzgerald, T. W., Kaplanis, J., Prigmore, E., Rajan, D., … Hurles, M. E. (2017). Prevalence and architecture of de novo mutations in developmental disorders. Nature, 542(7642), 433-438. https://doi.org/10.1038/nature21062</Citation>
        </Reference>
        <Reference>
          <Citation>Pastore, N., Vainshtein, A., Klisch, T., Armani, A., Huynh, T., Herz, N. J., … Ballabio, A. (2017). TFE3 regulates whole-body energy metabolism in cooperation with TFEB. EMBO Molecular Medicine, 9(5), 605-621. https://doi.org/10.15252/emmm.201607204</Citation>
        </Reference>
        <Reference>
          <Citation>Slade, L., &amp; Pulinilkunnil, T. (2017). The MiTF/TFE family of transcription factors: Master regulators of organelle signaling, metabolism, and stress adaptation. Molecular Cancer Research, 15(12), 1637-1643. https://doi.org/10.1158/1541-7786.MCR-17-0320</Citation>
        </Reference>
        <Reference>
          <Citation>Villegas, F., Lehalle, D., Mayer, D., Rittirsch, M., Stadler, M. B., Zinner, M., … Betschinger, J. (2019). Lysosomal signaling licenses embryonic stem cell differentiation via inactivation of Tfe3. Cell Stem Cell, 24(2), 257-270. https://doi.org/10.1016/j.stem.2018.11.021</Citation>
        </Reference>
        <Reference>
          <Citation>Yin, X., Wang, B., Gan, W., Zhuang, W., Xiang, Z., Han, X., &amp; Li, D. (2019). TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas. Journal of Experimental &amp; Clinical Cancer Research, 38(1), 119. https://doi.org/10.1186/s13046-019-1101-7</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
